Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,354 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infections. Clear all
Terminated Phase 2 Interventional Results available

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

NCT02388165
View directory record Official record
Conditions
Staphylococcal Vaccine
Interventions
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
234
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days

NCT00300677
View directory record Official record
Conditions
Infections, Fungal
Interventions
voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

NCT01484145
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine HCl
Drug
Lead sponsor
Nitric BioTherapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 1, 2026, 11:41 PM EDT
Completed No phase listed Observational

Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries

NCT05303662
View directory record Official record
Conditions
Drug Resistance, Multiple, Bacterial, Cholangiopancreatography, Endoscopic Retrograde
Interventions
Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs, MDRO-testing duodenal aspirate, Microbiome through rectal swab, Microbiome testing duodenal aspirate
Diagnostic Test
Lead sponsor
Marco J. Bruno
Other
Eligibility
18 Years and older
Enrollment
1,244 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 1, 2026, 11:41 PM EDT
Terminated Phase 4 Interventional

Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

NCT01196169
View directory record Official record
Conditions
Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Mountain Home Research & Education Corporation
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Johnson City, Tennessee • Mountain Home, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Tetracycline Treatment Tolerability Trial

NCT05219929
View directory record Official record
Conditions
Post-Treatment Lyme Disease
Interventions
Tetracycline 500 Mg, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

NCT04010539
View directory record Official record
Conditions
Gonorrhea
Interventions
Gepotidacin, Ceftriaxone, Azithromycin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Palm Springs, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection

NCT00132457
View directory record Official record
Conditions
Chlamydia Infections
Interventions
Self-collected vaginal swab for chlamydia testing
Procedure
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years and older · Female only
Enrollment
1,830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
New Orleans, Louisiana • Jackson, Mississippi • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

NCT00694629
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

NCT00323557
View directory record Official record
Conditions
Leukemia
Interventions
Sargramostim (GM-CSF), Pneumococcal Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Guidelines for Acute Sinusitis

NCT00132275
View directory record Official record
Conditions
Sinusitis
Interventions
Amoxicillin potassium clavulanate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Year to 10 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

NCT01404234
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 12 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 1, 2026, 11:41 PM EDT
Not listed Not applicable Interventional

Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures

NCT03744728
View directory record Official record
Conditions
Bloodstream Infection
Interventions
Accelerate PhenoTest™ BC kit, Standard of Care
Diagnostic Test
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

NCT05645757
View directory record Official record
Conditions
Bacterial Infection
Interventions
Ertapenem, Placebo, WCK 6777, Zidebactam
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

NCT03692871
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
22
States / cities
Downey, California • Huntington Beach, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 1, 2026, 11:41 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples

NCT02795975
View directory record Official record
Conditions
Chlamydia Trachomatis, Gonorrhea
Interventions
Not listed
Lead sponsor
Hologic, Inc.
Industry
Eligibility
14 Years and older · Female only
Enrollment
1,766 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000636
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
25
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002032
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Irvine, California • Sylmar, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains

NCT02968758
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Comparison between GenePOC PCR and Reference Method
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
Not listed
Enrollment
2,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 4 Interventional

Animal-Assisted Visitation Program Chlorhexidine Trial

NCT04171817
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
Interventions
Chlorhexidine
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
3 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 1, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
NDV-3A, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
17 Years to 35 Years · Male only
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Benning, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 1, 2026, 11:41 PM EDT
Recruiting Phase 2 Interventional

Olorofim in Early Coccidioidal Meningitis

NCT07385638
View directory record Official record
Conditions
Coccidioidal Meningitis
Interventions
olorofim
Drug
Lead sponsor
Fariba Donovan
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 1, 2026, 11:41 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Novel Diagnostics for Early Lyme Disease

NCT03963635
View directory record Official record
Conditions
Lyme Disease
Interventions
MicroB-plex Lyme Immunoassay
Diagnostic Test
Lead sponsor
MicroB-plex, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 1, 2026, 11:41 PM EDT